Excellergy

Palo Alto, United States

Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.

$70.0M raised

Oct 2025

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Excellergy raised?

Excellergy has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.

Who are Excellergy's investors?

Excellergy's investors include Samsara BioCapital, Decheng Capital, Red Tree Venture Capital.

Where is Excellergy headquartered?

Excellergy is headquartered in Palo Alto, United States.

What does Excellergy do?

Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.

What stage is Excellergy at?

Excellergy is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 13, 2025.

MLA

"Excellergy — Funding & Investors." VCBacked, October 13, 2025, https://www.vcbacked.co/company/excellergy. Accessed July 2, 2026.

APA

VCBacked. (2025). Excellergy — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/excellergy

Wikipedia (cite web)

{{cite web |title=Excellergy — Funding & Investors |url=https://www.vcbacked.co/company/excellergy |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 13, 2025.